<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24956">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01776814</url>
  </required_header>
  <id_info>
    <org_study_id>GAIRB2963-2012</org_study_id>
    <nct_id>NCT01776814</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-na√Øve Patients With Chronic Hepatitis B in Korea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis B virus infection is an important cause of morbidity and mortality.
      Tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis B
      virus infection. In this study, the investigators will try to make comparison between
      Entecavir and Tenofovir and investigate the efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>virologic response</measure>
    <time_frame>changes from baseline HBV DNA level at 3, 6, 9, 12 months after taking entecavir or tenofovir</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will check the HBV DNA level at 3, 6, 9, 12 months after taking entecavir and tenofovir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction of alanine transaminase</measure>
    <time_frame>changes from baseline ALT level at 3,6,9,12 months after taking entecavir or tenofovir</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will check the level of alanine transaminasel at 3, 6, 9, 12 months after taking entecavir and tenofovir</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        treatment of nucleos(t)ide-naive patients who were diagnosed with chronic hepatitis B in
        Korea
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 &lt; Age &lt; 70

          -  HBV DNA &gt; 100,000 copies/mL and increased ALT over 2 times compared with normal range
             if HBsAg (+), HBeAg (+)

          -  HBV DNA &gt; 10,000 copies/mL and increased ALT compared with normal range if HBsAg (+),
             HBeAg (-)

        Exclusion Criteria:

          -  With HCV  or other liver disease

          -  With kidney disease

          -  decompensated liver cirrhosis

          -  with hepatocellular carcinoma

          -  refuse this clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ju Seung Kim, Fellow</last_name>
    <phone>+80+32 460 2792</phone>
    <email>joojoomj@gilhospital.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center, Department of Gastroenterology</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ju Seung Kim, Fellow</last_name>
      <phone>+82 +32 460 2792</phone>
      <email>joojoomj@gilhospital.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 25, 2013</lastchanged_date>
  <firstreceived_date>January 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Ju Seung Kim, MD</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <keyword>Entecair</keyword>
  <keyword>Tenofovir</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
